Abstract
Cardiovascular disease (CVD) is one of the leading causes of death worldwide. According to the World Health Organization, in 2016 about 17.9 million people died from CVD, and this accounted for 31% of all deaths in the world. Dyslipidemia is one of the main risk factors of atherosclerosis, asymptomatic and acute ischemic heart disease (IHD), cerebrovascular accidents, and sudden cardiac death. The results of multicenter clinical trials (RCT) conducted in the Russian Federation and abroad have demonstrated that one of the effective methods of primary and secondary prevention of CVD, as well as reducing the risk of complications in the high and very high-risk patients, is the use of lipidlowering drugs belonging to HMG-CoA reductase inhibitors (statins). The article presents the results of an analysis of publications describing the safety of Atorvastatin, recognized as one of the most effective drugs in the group. Particular attention is paid to the mechanisms of insulin resistance, hepatotoxicity and statin-induced myopathies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Crimea Journal of Experimental and Clinical Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
